Sanofi Keeps Pricing Commitment
July 20, 2018
Sanofi, the parent company of Sanofi Genzyme, recently released its Sanofi 2018 Pricing Principles Report: Advancing Responsible Leadership
, keeping the commitments the company made in releasing pricing principles last year. Prices for the company’s two MS products, Aubagio and Lemtrada, each increased by 5%.
In its principles, Sanofi promised to:
- provide clear rationale for initial pricing of a medication;
- benchmark price increases to below the rate of health inflation (around 5.4% in 2017) or provide clear rationale for any exceptions; and
- provide greater transparency on prices overall.
“It’s important for everyone involved in the prescription drug supply chain to do their part in improving access and affordability of life-changing medications for those who rely on them,” said Bari Talente, Executive Vice President, Advocacy for the National MS Society. “While we are working towards the point where MS disease modifying medications are not incurring price increases year over year, we recognize that these products have been on the market for less than 6 years and Sanofi is actually facing a net decrease with price increases at 5%.”
“The National MS Society thanks Sanofi for striving to be a leader in the complex landscape of drug prices and transparency.” Talente continued. “We encourage other parties involved within the healthcare system to follow suit and put patients at the forefront in their decision-making.”
Sanofi’s principles align with the National MS Society’s Make Medications Accessible Initiative
and are part of the changes necessary to ensure that medications are affordable, and the process for getting them is simple and transparent.